Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous HIV-1 antigen-pulsed dendritic cell vaccine (UNIFESP)
- Development stage
- Unknown
- Lead developer
- Federal University of São Paulo
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This personalized autologous dendritic cell vaccine is an investigational immunotherapy developed by the Federal University of São Paulo (UNIFESP) in collaboration with the São Paulo AIDS Research Center (SPARC) for the treatment and potential eradication of HIV-1. The vaccine is produced by isolating a patient's monocytes, differentiating them into dendritic cells ex vivo, and pulsing them with a cocktail of HIV-1 antigens, specifically the Gag, Vpr, Vif, and Nef proteins. Upon re-administration, these dendritic cells act as potent antigen-presenting cells to prime and expand HIV-specific CD4+ and CD8+ T-cell responses. The vaccine is currently being evaluated in the SPARC-7 clinical trial as part of a multi-pronged 'shock and kill' strategy that includes antiretroviral therapy intensification (Maraviroc and Dolutegravir) and the use of latency-reversing or purging agents (nicotinamide and auranofin) to target the latent HIV reservoir.
- Other names
- dendritic cell vaccine (UNIFESP)autologous dendritic cell vaccine (SPARC-7)SPARC-7 vaccineSPARC7 vaccineSPARC 7 vaccine
Beyond the preview
Go deeper on autologous HIV-1 antigen-pulsed dendritic cell vaccine (UNIFESP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous HIV-1 antigen-pulsed dendritic cell vaccine (UNIFESP).